Scancell Holdings Share News (SCLP)

Scancell Expects SCIB1 Clinical Study Report In First Half Of 2016

AGM, EGM Calendar - Week Ahead

Bigger loss but positive drug trial results for Scancell Holdings

(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials

Scancell Holdings Loss Wider On Higher Development Costs

Scancell Signs Research Collaboration Deal With ImmunID

Scancell Closes Patient Recruitment For Next Phase Of SCIB1 Trials

Scancell gives positive update on melanoma treatment data

Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The data showed that all 16 patients with re

Scancell Reports Encouraging Ongoing SCIB1Trial Results

Scancell Says New Data Supports SCIB2 Combination Treatment

Scancell Sees Positive Data In On-Going Phase I/2 SCIB1Trial

UK MIDDAY BRIEFING: Life's No Catwalk For Luxury Goods Makers

UK WINNERS & LOSERS: Miners Continue Run, Oil Companies Fall

Scancell Shares Boosted By Positive SCIB-1 Trial Results

UK MORNING BRIEFING: Burberry And Hargreaves Lansdown Lead Declines

UK AGM, EGM Calendar - Week Ahead